Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

RAD American Depositary Receipt (ADR) FAQs

Friday, January 10, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress by dosing the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to begin a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared across four of its programs, indicating a strong pipeline.
Price reaction · baseline $5.2197 (2025-01-10T20:32:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
+2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates across four programs were provided.

Full Press Release Details

• Updates
• PDF
• January 10, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• August 23, 2024
• Announcements
• July 1, 2022
• Announcements
• June 25, 2024
• Announcements
• October 26, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart (RV-01) clinical study?

The BetaBart (RV-01) clinical study is a Phase 1/2a trial initiated by Radiopharm Theranostics.

What recent FDA approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3.

How many programs received positive updates?

Radiopharm provided positive clinical updates across four of its programs.

When was the first patient dosed in the study?

The first patient was dosed in the Phase 1/2a clinical study on October 20, 2025.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical study
Last updated: Jan 10, 2025